Synthetic pharmaceutical chemicals class 1.1 new drug - Disodium l-ornidazole phosphate - approved clinical trial

Announcement of synthetic pharmaceutical industry (832077) on June 23 According to the statement, the company's declared new chemical drug of class 1.1, "disodium l-ornidazole phosphate and disodium l-ornidazole phosphate for injection", has obtained the approval document for clinical trials of drugs issued by the State Food and Drug Administration (approval opinion no of API: 2015l01090; clinical approval document No of preparation: 2015l01091), and approved the product for clinical trials The data show that ornidazole is a commonly used anti anaerobe drug As the third generation anti anaerobe drug after metronidazole and Tinidazole, its curative effect is positive and side effect is small It has achieved better effect in clinical and is widely recognized According to the company, l-ornidazole phosphate disodium is a new compound formed by the chemical structure modification of l-ornidazole phosphate (patent number of l-ornidazole phosphate disodium compound: zl200610166893.2, zl200710188487.0) The pharmacokinetic study shows that l-ornidazole phosphate disodium can be rapidly decomposed into l-ornidazole in vivo.